Abdulghani A Naeem^1,2, Saud A Abdulsamad^1,2*, Youqiang Ke3 and Gang He⁴

¹Basic Sciences Department, College of Science and Health Professions, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
²King Abdullah International Medical Research Center, Jeddah, Saudi Arabia
³Department of Molecular and Clinical Cancer Medicine, Liverpool University, Liverpool, UK
⁴Sichuan Industrial Institute of Antibiotics, Chengdu University, Chengdu, Sichuan, China

*Corresponding Author: Saud A Abdulsamad, Basic Sciences Department, College of Science and Health Professions, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.

Received: March 07, 2024; Published: April 26, 2024

Abstract

Since the 1970s, molecular scientists have been searching for methods to modify DNA via biological repair processes. Thus, they would be able to fix genetic mutations or introduce new functions into the genome. In order to accomplish this goal, genome editing techniques were created. It has become considerably easier, more accurate, and less costly to modify the genome because to the advent of new techniques. There has been a surge in interest in genome editing's potential uses since these breakthroughs, both for basic research and for improving human health through treating or preventing illness and disability. Scientists may now modify DNA to alter physical characteristics like eye color and the likelihood of contracting illness thanks to advances in genome editing technology. Various methods are used by scientists to do this. Every medical advancement has its own set of advantages, hazards, regulatory difficulties and ethical issues that must be taken into consideration while using it. Genome editing raises a number of important challenges, including how to balance possible advantages against the danger of unintended damage; how to manage the usage of these techniques; how to include cultural values into pertinent medical and economic considerations; as well as how to respect the unavoidable disparities, founded in country cultures, that will impact attitudes on whether as well as how to utilize these technologies. The purpose of this study is to discuss the most recent advances in gene editing, as well as the potential benefits and drawbacks that may result from its use.

Keywords: Gene Editing; Homologue; Antisense; mRNA; RNAi; Mutagenesis

References

1. Cox DBT., et al. “Therapeutic genome editing: prospects and challenges”. Nature Medicine2 (2015): 121-131.
2. Cooney AL., et al. “Cystic fibrosis gene therapy: looking back, looking forward”. Genes11 (2018): 538 (2018).
3. Adli M. “The CRISPR tool kit for genome editing and beyond”. Nature Communications 9 (2018):
4. King NMP., et al. “Editing the Genome: Prospects, Progress, Implications, and Cautions”. Current Genetic Medicine Reports 5 (2017): 35-43.
5. Ranjha L., et al. “Main steps in DNA double-strand break repair: an introduction to homologous recombination and related processes”. Chromosoma127 (2018): 187-214.
6. Sung P and Klein H. “Mechanism of homologous recombination: mediators and helicases take on regulatory functions”. Nature Reviews Molecular Cell Biology 7 (2006): 739-750.
7. Heyer WD., et al. “Regulation of homologous recombination in eukaryotes”. Annual Review of Genetics 44 (2010): 113-139.
8. Lord C and Ashworth A. “The DNA damage response and cancer therapy”. Nature481 (2012): 287-294.
9. Gerlai R. “Gene Targeting Using Homologous Recombination in Embryonic Stem Cells: The Future for Behavior Genetics?” Frontiers in Genetics 7 (2016): 43.
10. Capecchi M. “Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first century”. Nature Reviews Genetics 6 (2005): 507-512.
11. Cheah SS and Behringer RR. “Gene-targeting strategies”. Methods in Molecular Biology 136 (2000): 455-463.
12. González-Torres P., et al. “Impact of homologous recombination on the evolution of prokaryotic core genomes”. MBio1 (2003): e02494-02518.
13. Shibata T., et al. “Homologous genetic recombination as an intrinsic dynamic property of a DNA structure induced by RecA/Rad51-family proteins: a possible advantage of DNA over RNA as genomic material”. Proceedings of the National Academy of Sciences15 (2001): 8425-8432.
14. Sukhodelets VV. “Importance of genetic recombination for the preservation and progress of species in the course of evolution”. Zhurnal Obshchei Biologii 3 (2003): 215-226.
15. Kondrashov AS. “Deleterious mutations as an evolutionary factor: 1. The advantage of recombination”. Genetics Research2 (1984): 199-217.
16. Ragu S., et al. “Homologous recombination in mammalian cells: From molecular mechanisms to pathology”. In Genome Stability (2021): 367-392.
17. Faure E., et al. “Probable presence of an ubiquitous cryptic mitochondrial gene on the antisense strand of the cytochrome oxidase I gene”. Biology Direct1 (2011): 1-22.
18. Wang TZ., et al. “Identification and characterization of long non-coding RNAs involved in osmotic and salt stress in Medicago truncatula using genome-wide high-throughput sequencing”. BMC Plant Biology1 (2015): 1-3.
19. Chan JH., et al. “Antisense oligonucleotides: from design to therapeutic application”. Clinical and Experimental Pharmacology and Physiology 5‐6 (2006): 533-540.
20. Uguru GC., et al. “Synthetic RNA silencing of actinorhodin biosynthesis in Streptomyces coelicolor A3 (2)”. PLoS One6 (2013): e67509.
21. Li M., et al. “Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra-and paracellular pathways”. Journal of Controlled Release228 (2016): 9-19.
22. Kher G., et al. “Antisense oligonucleotides and rna interference”. Challenges in Delivery of Therapeutic Genomics and Proteomics (2011): 325-386.
23. Hoyer JA and Neundorf I. “Peptide vectors for the nonviral delivery of nucleic acids”. Accounts of Chemical Research7 (2012): 1048-1056.
24. De Martimprey H., et al. “Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA”. European Journal of Pharmaceutics and Biopharmaceutics3 (2009): 490-504.
25. Martínez MA., et al. “Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication”. Aids18 (2002): 2385-2390.
26. Ambros V and Lee RC. “Identification of microRNAs and other tiny noncoding RNAs by cDNA cloning”. InRNA Interference, Editing, and Modification (2004): 131-158.
27. Amarzguioui M., et al. “Approaches for chemically synthesized siRNA and vector-mediated RNAi”. FEBS letters26 (2005): 5974-5981.
28. Rand TA., et al. “Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity”. Proceedings of the National Academy of Sciences40 (2004): 14385-14389.
29. Ramalingam P., et al. “Biogenesis of intronic miRNAs located in clusters by independent transcription and alternative splicing”. RNA1 (2014): 76-87.
30. Yoo BK., et al. “Increased RNA‐induced silencing complex (RISC) activity contributes to hepatocellular carcinoma”. Hepatology5 (2011): 1538-1548.
31. Li C., et al. “Differential microRNA expression, microRNA arm switching, and microRNA: long noncoding RNA interaction in response to salinity stress in soybean”. BMC Genomics1 (2022): 1-3.
32. Blair CD and Olson KE. “The role of RNA interference (RNAi) in arbovirus-vector interactions”. Viruses 2 (2015): 820-843.
33. Hutvagner G and Zamore PD. “A microRNA in a multiple-turnover RNAi enzyme complex”. Science5589 (2002): 2056-2060.
34. Ambros V., et al. “MicroRNAs and other tiny endogenous RNAs in C. elegans”. Current Biology10 (2013): 807-818.
35. Saetrom P., et al. “Epigenetics and microRNAs”. Pediatric Research 7 (2007): 17-23.
36. DasGupta R and Gonsalves FC. “High-throughput RNAi screen in Drosophila”. InWnt Signaling (2008): 163-184.
37. Krueger U., et al. “Insights into effective RNAi gained from large-scale siRNA validation screening”. Oligonucleotides2 (2007): 237-250.
38. Schäffner AR and Sheen J. “Maize rbcS promoter activity depends on sequence elements not found in dicot rbcS promoters”. The Plant Cell9 (1991): 997-1012.
39. Ceasar SA., et al. “Insert, remove or replace: A highly advanced genome editing system using CRISPR/Cas9”. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research9 (2016): 2333-2344.
40. Strzyz P. “CRISPR-Cas9 wins Nobel”. Nature Reviews Molecular Cell Biology12 (2020): 714.
41. Hsu PD., et al. “Development and applications of CRISPR-Cas9 for genome engineering”. Cell6 (2014): 1262-1278.
42. Long C., et al. “Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA”. Science6201 (2014): 1184-1188.
43. Cyranoski D and Reardon S. “Chinese scientists genetically modify human embryos”. Nature 22 (2015).
44. Cribbs AP and Perera SM. “Focus: Genome editing: Science and bioethics of CRISPR-Cas9 gene editing: An analysis towards separating facts and fiction”. The Yale Journal of Biology and Medicine 4 (2017): 625.
45. Rath J. “Safety and security risks of CRISPR/Cas9”. InEthics Dumping (2018): 107-113).
46. Gelot C., et al. “Double-Strand Break Repair: Homologous Recombination in Mammalian Cells”. In Genome Stability (2006): 337-351.
47. Kurreck J. “Antisense technologies: improvement through novel chemical modifications”. European Journal of Biochemistry8 (2003): 1628-1644.
48. Agrawal N., et al. “RNA interference: biology, mechanism, and applications”. Microbiology and Molecular Biology Reviews4 (2003): 657-685.
49. Castorena‐Torres F., et al. “Site‐Directed Mutagenesis by Polymerase Chain Reaction”. Polymerase Chain Reaction for Biomedical Applications (2006).
50. IDT_ CRISPR Basic Handbook.
51. IDT_ CRISPR Basic Handbook.
52. IDT _CRISPR Basic Handbook.
53. https://sg.idtdna.com/pages/education/decoded/article/are-you-still-using-crispr-plasmids-consider-ribonucleoprotein- (rnp)-instead!

Citation

Citation: Saud A Abdulsamad., et al. “Gene Editing Technique: Homologue Recombination, Antisense mRNA, RNAi, Site-Directed Mutagenesis, and CRISPR/Cas9".Acta Scientific Microbiology 7.5 (2024): 35-45.

Copyright

Copyright: © 2024 Saud A Abdulsamad., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.